What is the effectiveness of lvosidenib?

The complete remission rate was 47.2% in the ivonib plus azacitidine group and 14.9% in the placebo plus azacitidine group. The overall effective rates were 62.5% and 18.9%, respectively. The median duration of treatment with ivonib plus azacitidine was 6 months, and the median duration of treatment with placebo plus azacitidine was 2.8 months. The U.S. Food and Drug Administration approvesivosidenibfor the treatment of patients with relapsed or refractory(R/R)myelodysplastic syndrome span>(MDS) in adult patients with isocitrate dehydrogenase-1 detected in an FDA-approved test (IDH1)Mutation. If you want to get more high-quality information, you can contact Yaodede. Yaode will do its best to learn more about high-quality overseas drugs for you.